Innovation in liquid biopsy to eradicate cancer
Novigenix is an innovative Swiss molecular diagnostics company specializing in liquid biopsy for early detection of cancer. The society develops new generation blood tests.
Novigenix’s technology is based on a new generation of gene expression profiles of circulating blood cells and tumor-derived protein markers in combination with state-of-the-art mathematical analytical models.
Our predictive molecular signatures provide new and accurate solutions for the early detection of cancer.
Colox®, our lead product is a proven molecular blood test designed to significantly reduce mortality from colorectal cancer through early detection and follow-up colonoscopy.
Commitment and strategy
“ Our vision is to support physicians and the healthcare community in significantly
reducing cancer mortality through the early diagnosis ” B. Hashemi – Chairman
As a biotech start-up, it is in our nature to be agents of change and we therefore see it as our mission to rewrite the rules of the game. Colorectal cancer kills 1,600 people in Switzerland every year. Early detection increases the chance of survival to 90%, but only 30% of the Swiss population gets screened. This is crazy.
Since early detection is the solution to saving lives, we are committed to encouraging everyone by whatever mean to:
- get themselves screened regularly if they are over 50
- get their loved ones to get screened.
Colonoscopy, stool analysis or blood test: it doesn’t matter which method you choose, what matters is to get screened.
For our part, we have developed Colox, a new-generation blood test that makes colorectal cancer screening simple and clean for all (but it is not yet reimbursable by your insurance).
The challenge that motivates us is to create a momentum towards eradicating avoidable deaths. Parents, friends, colleagues, neighbours… everybody needs to know! And everybody needs to get screened!
Together, let’s win the Colorectal Challenge!
We talk about it on:
Colorectal Cancer Dx Firm Novigenix Looks to Expand Market for Blood Test in Switzerland, Europe…
Die Darmkrebsvorsorge ist freiwillig – Ärzte und Präventionsmediziner raten aber dringend dazu….
NEW YORK (GenomeWeb) – With a new CEO at its helm, Swiss molecular diagnostic firm Novigenix is developing a new version of Colox, its mRNA-based assay for early colorectal cancer detection that applies next-generation sequencing instead of RT-PCR.
Dr. Marianne Murphy
Immunologist with international recognition in the fields of T cell and cytokine biology, and with 25 years of industry experience in various leading positions at NatiMab Therapeutics, RiboVax Biotechnologies, and Celltech R&D.
Dr. Reinhard Ebner
Senior research manager and investigator specialized in solving complex questions in molecular and cell biology, particularly as they relate to disease mechanism and drug discovery. More than 30 years of experience in US academia and industrie (Stanford, Genentech, NIH, Cytotest).
Prof. Stephan Morgenthaler
Full Professor at Ecole Polytechnique Fédérale de Lausanne (EPFL), Chair of Applied Statistics, Lausanne, Switzerland
Dr. Antoine de Weck
Investigator at Novartis Institute for Biomedical Research and specialist in Computational Biology, Basel, Switzerland
Prof. Christoph Beglinger, MD
Specialist in Gastroenterology, formerly Head of the Department of Biomedicine at the University Hospital of Basel, currently Head of Clinical Research at St. Claraspital in Basel, Switzerland
Prof. Gian Dorta, MD
Specialist in Gastroenterology, Department of Internal Medicine, Section Gastroenterology and Hepatology, Academic Medical Center, Lausanne (CHUV), Switzerland
Dr. Cristina Nichita, MD
Specialist in Gastroenterology, Centre Médical d’Epalinge, VIDY MED Group, Epalinges, Switzerland
Prof. Peter Bauerfeind, MD
Specialist in Gastroenterology, Clinic for Gastroenterology and Hepatology, University Hospital, Zurich (USZ), Switzerland
Dr. Philippe Maerten, MD PhD
Specialist in Gastroenterology, Hirslanden Clinic Cecil, Lausanne, Switzerland